The company is involved in clinical research, managing assets and liabilities, and preparing for potential health-related developments, but specific operational details are not provided.

# Company Business Summary

The provided information primarily lists the sections of the company's annual report (specifically Part I, Item 1 - Business, Item 1A - Risk Factors, etc.) along with page references. However, it does not include specific details about the company's operations, such as its industry, products and services, number of customers, employees, revenue, or income.

### Summary:
- The company’s detailed business operations are described in **Part I, Item 1** of the report.
- The report contains sections on risk factors, cybersecurity, properties, legal proceedings, and mine safety disclosures.
- No specific operational or financial data (such as number of customers, employees, revenue, or income) is provided within the given excerpt.

**Note:** To provide a comprehensive summary of what the company does, additional details from Part I, Item 1 of the report are necessary.

Burzynski Research Institute, Inc. is a biotechnology firm focused on the research and development of Antineoplastons, which are believed to be effective in cancer treatment but are not FDA-approved for commercial use.

# Summary of Burzynski Research Institute, Inc.

## General Overview
Burzynski Research Institute, Inc. (the "Company") is a biotechnology firm incorporated in Delaware in 1984. The main focus of the Company is the research, production, marketing, promotion, and sale of medical chemical compounds known as Antineoplastons, which are composed of growth-inhibiting peptides, amino acid derivatives, and organic acids. 

### Antineoplastons
- The Company believes these compounds are effective in the treatment of various human cancers.
- Antineoplastons have not been approved for sale or use by the FDA or other regulatory bodies worldwide.
- They have received “orphan drug designation” from the FDA for specific cancer treatments.
- The Company is currently utilizing Antineoplastons solely for clinical research purposes at Dr. Stanislaw R. Burzynski’s clinic in Houston, Texas.

## Research and Clinical Trials
- Dr. Burzynski started his cancer research in 1967, leading to the identification of Antineoplastons.
- The Company has conducted multiple clinical trials (Phase II and attempted Phase III) involving various formulations of Antineoplastons, particularly focusing on brain tumors such as gliomas and brainstem gliomas.
- As of February 29, 2024, the Company has accrued a total of **2,298 patients** who have received at least one dose of Antineoplastons.
- The trials reported significant cases of objective responses (complete or partial responses) in various cancer types but have had clinical holds imposed by the FDA due to issues with the manufacturing facility and other regulatory concerns.

### Publications and Research Output
- The results of the Company's clinical trials and studies have led to **34 publications** in peer-reviewed medical journals detailing their findings.

## Financial Overview
- The Company has **no significant operating revenue** since its inception, relying mainly on funding from Dr. Burzynski’s private medical practice.
- Anticipated funding will be necessary to continue research and operations, including potential additional financing through the sale of securities.

## Employment
- As of February 29, 2024, the company has **no full-time employees** and does not intend to employ full-time staff. 

### Operating Capital
- The financing structure primarily consists of payments made by Dr. Burzynski, classified as additional paid-in capital, but the Company may seek additional capital through securities offerings as needed and where feasible.

## Key Metrics
- **Number of Customers/Patients Treated**: 2,298
- **Employees**: 0 (no full-time employees)
- **Operating Revenue**: None reported
- **Funding Source**: Primarily from Dr. Burzynski's medical practice

Overall, Burzynski Research Institute, Inc. focuses on the development of Antineoplastons as potential cancer treatments while navigating both clinical and regulatory challenges, providing insights into the use and efficacy of these compounds through ongoing research and peer-reviewed publications.

BURZYNSKI RESEARCH INSTITUTE INC

10-K / May 20, 2025

10-K / May 29, 2024

10-K / May 20, 2025

Company Business Summary

Summary: